53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)
A. Vogel, P. Wenzel, G. Folprecht, P. Schütt, H. Wege, A. Kretzschmar, L. Jacobasch, N. Ziegenhagen, S. Boeck, S. Kanzler, J. Mohm, S. Belle, Daniel Pink, T.O. Götze, E. Goekkurt, U. Graeven, M. Schaaf, M. Kirstein, A. Saborowski
Topics & Concepts
MedicineGemcitabineInternal medicineClinical endpointAdverse effectGallbladder cancerGallbladderGastroenterologyIrinotecanPhases of clinical researchRandomized controlled trialOncologyClinical trialSurgeryCancerColorectal cancerCholangiocarcinoma and Gallbladder Cancer StudiesPeptidase Inhibition and AnalysisGallbladder and Bile Duct Disorders